n-valproyl-glycinamide and Alzheimer-Disease

n-valproyl-glycinamide has been researched along with Alzheimer-Disease* in 1 studies

Reviews

1 review(s) available for n-valproyl-glycinamide and Alzheimer-Disease

Article	Year
Valrocemide (Teva/Acorda). Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:1 Valrocemide is an anticonvulsant agent under development by Teva and Acorda as a potential therapeutic for the treatment of epilepsy. In October 2003, a phase II trial using valrocemide as an adjunct therapy in refractory epilepsy patients had been completed and phase III trials were being planned. Valrocemide was also being investigated for potential utility in the treatment of bipolar disorder and neuropathic pain. Topics: Alzheimer Disease; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Glycine; Humans; Patents as Topic; Structure-Activity Relationship	2004

Article

Year

Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:1

Valrocemide is an anticonvulsant agent under development by Teva and Acorda as a potential therapeutic for the treatment of epilepsy. In October 2003, a phase II trial using valrocemide as an adjunct therapy in refractory epilepsy patients had been completed and phase III trials were being planned. Valrocemide was also being investigated for potential utility in the treatment of bipolar disorder and neuropathic pain.

Topics: Alzheimer Disease; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Glycine; Humans; Patents as Topic; Structure-Activity Relationship

2004